Skip to main content
Harry Malech, MD, Infectious Disease, Bethesda, MD

HarryLMalechMD

Infectious Disease • Bethesda, MD

Physician

Join to view full profile

Dr. Malech is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Malech's full profile

Already have an account?

  • Office

    10 Center Dr
    Bldg 10 RM 53750 Msc1456 Nih
    Bethesda, MD 20892
    Phone+1 301-480-6916
    Fax+1 301-402-0789

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1972 - 1974
  • Yale School of Medicine
    Yale School of MedicineClass of 1972

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1986 - 2025
  • PA State Medical License
    PA State Medical License 1973 - 1976
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1988

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Novel Method for Screening Adenosine Receptor Specific Agonists for Use in Adenosine Drug Development  
    Harry Malech, MD, Nature

Abstracts/Posters

  • Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model
    Harry L. Malech, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing P...
    Harry L. Malech, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency
    Harry L. Malech, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Development of a Clinically Applicable Method for High-Efficiency Gene Correction of Plerixafor-Mobilized CD34+ Cells from Patients with Sickle Cell Disease 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Waning Treatment for Immune Deficiency Is a Warning for All ‘One-and-Done’ Therapies
    Waning Treatment for Immune Deficiency Is a Warning for All ‘One-and-Done’ TherapiesDecember 19th, 2019
  • SIRION Biotech Licenses Technology to National Institute of Allergy and Infectious Diseases to Boost Clinical Efficacy of Lentivector Gene Therapy for X-linked SCID
    SIRION Biotech Licenses Technology to National Institute of Allergy and Infectious Diseases to Boost Clinical Efficacy of Lentivector Gene Therapy for X-linked SCIDJune 11th, 2019
  • Gene Therapy Cures Babies with “Bubble Boy” Disease
    Gene Therapy Cures Babies with “Bubble Boy” DiseaseApril 19th, 2019
  • Join now to see all

Grant Support

  • Basic Research On Hematopoietic Human Stem CellsNational Institute Of Allergy And Infectious Diseases2009–2011
  • Gene Therapy Basic Research To Treat Inherited Immune DeficienciesNational Institute Of Allergy And Infectious Diseases2007–2008
  • Clinical Treatment Of Patients With Chronic Graft Versus Host DiseaseNational Institute Of Allergy And Infectious Diseases2007–2008
  • Basic Research On Hematopoietic Adult Human Stem CellsNational Institute Of Allergy And Infectious Diseases2007–2008
  • Gene Therapy Clinical Trials For X-Linked Severe Combined ImmunodeficiencyNational Institute Of Allergy And Infectious Diseases2007
  • Clinical Diagnostic Studies And Treatment Of Patients With Immune DeficienciesNational Institute Of Allergy And Infectious Diseases2007
  • Gene Therapy And Allogeneic Transplantation For Immune DNational Institute Of Allergy And Infectious Diseases2006
  • Biology Of Peripheral Blood Progenitors--A Target For GENational Institute Of Allergy And Infectious Diseases2002–2006
  • Biology Of Peripheral Blood ProgenitorsNational Institute Of Allergy And Infectious Diseases2005
  • Gene Therapy For Immune DeficienciesNational Institute Of Allergy And Infectious Diseases1992–2005
  • Peripheral Blood Progenitors--Target For Gene TransferNational Institute Of Allergy And Infectious Diseases2004
  • Biology Of Peripheral Blood Progenitors In Gene TransferNational Institute Of Allergy And Infectious Diseases2003
  • Peripheral Blood Progenitors--A Target For Gene TransferNational Institute Of Allergy And Infectious Diseases2001
  • Biology Of Peripheral Blood Progenitors--A Target For Gene TransferNational Institute Of Allergy And Infectious Diseases1992–2000
  • Peripheral Blood Progenitors-Target For Gene TransferNational Institute Of Allergy And Infectious Diseases1998
  • Zotatifin treatment of adults with mild to moderate COVID-19NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
  • Gene Therapy and Hematopoietic Stem Cell Research to Treat Inherited Primary Immune DeficienciesNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent

Dr. Harry Malech, Dr. Harry Malech, MD, Dr. H Malech, Dr. Harry L Malech